Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
159
datasets available to search
ShareScore release 0.9.0
Dataset results
159 results for “anxiety symptoms”
The relationship between linguistic expression and symptoms of depression, anxiety, and suicidal thoughts: A longitudinal study of blog content
<p>To investigate the associations between linguistic features and symptoms of depression, generalised anxiety, and suicidal ideation, we extracted linguistic features from individuals’ blog content and correlated it with validated mental health data in a longitudinal study (n=38). Depressive symptoms were assessed using the self-report Patient Health Questionnaire (PHQ-9), anxiety symptoms using the self-report Generalised Anxiety Disorder Scale (GAD-7), and social media data was analysed using the Linguistic Inquiry and Word Count (LIWC) tool for linguistic features. Bivariate and multivariate analyses were performed to investigate the correlations between the linguistic features and mental health scores between subjects. We then used the multivariate regression model to predict longitudinal changes in mood within subjects.</p>
The prevalence and correlates of depression and anxiety symptoms among older adults in Shenzhen, China
<p><strong>Objectives: </strong>To investigate the prevalence of depression and anxiety symptoms among older adults in an urban district in China, as well as their associated factors.</p> <p><strong>Participants:</strong> A total of 5,372 community-dwelling older adults aged 65 years or older were initially recruited. Ultimately, 5,331 participants met the inclusion criteria and were included in this study.</p> <p><strong>Methods:</strong> Participants completed a sociodemographic questionnaire, along with assessments including the Patient Health Questionnaire-9, Generalized Anxiety Scale-7, UCLA Loneliness Simplification Scale, Insomnia Severity Index Scale, Community Dementia Brief Screening Scale, and the 8-item Dementia Screening Questionnaire. Statistical analyses included the Shapiro‒Wilk test, independent t-test, Wilcoxon rank test, c<sup>2</sup> test, and univariate and multivariate linear regression analysis.</p> <p><strong>Results:</strong> The prevalence of depression and anxiety symptoms among older adults in Shenzhen communities was 10.4% and 11.3%, respectively. In multivariate analysis, age (B=-0.01, <em>P</em><0.05), relatively poor health status in the past year (B=1.00, <em>P</em><0.01), poor health status in the past year (B=2.40, <em>P</em><0.01), ISI score (B=0.21, <em>P</em><0.01), AD8 score (B=0.22, <em>P</em><0.01), ULS score (B=0.24, <em>P</em><0.01) were significantly associated with the severity of depression symptom, Compared to their respective reference categories, relatively poor health status in the past year (B=0.50, <em>P</em><0.01), poor health status in the past year (B=1.32, <em>P</em><0.01), ISI score (B=0.23, <em>P</em><0.01), sleep duration (B=0.05, <em>P</em><0.01), AD8 score (B=0.21, <em>P</em><0.01), CSID score (B=0.13, <em>P</em><0.01), ULS score (B=0.22, <em>P</em><0.01) were significantly associated with the severity of anxiety symptom.</p> <p><strong>Conclusions: </strong>We observed a high prevalence of depression and anxiety symptoms among older adults in this study. The existing welfare system and infrastructure should remain and targeted mental health programs addressing the identified risk factors should be proposed.</p>
Self-medication for anxiety symptoms in the context of COVID-19, in users who go to a drugstore in Los Olivos, Lima-2021
<p><strong>Background:</strong> To determine the relationship between self-medication and anxiety symptoms in the context of COVID-19, in users who go to a drugstore in Los Olivos, Lima 2021.</p> <p><strong>Methods:</strong> The research method was deductive, basic and with a quantitative approach; the design used was non-experimental, descriptive, correlational, cross-sectional, and prospective. Spearman's Rho analysis was performed to validate the hypothesis.</p> <p><strong>Results:</strong> 384 users were evaluated, finding 93.5% aged 18-59 years, of whom 53.4% were female, 42.7% had completed high school, 57.8% were single and 51.6% presented physical symptoms, preferably muscular tension accompanied by pain, 60.7% presented behavioral symptoms, highlighting unusual sadness in the face of COVID-19 and 70.1% presented cognitive symptoms with greater frequency of concern about contracting COVID-19. In addition, the greater the symptoms of anxiety, the higher the self-medication increased from 9.0% to 21.1%, a similar case was evidenced in self-medication on their own initiative where the increase was from 7.5% to 33.3%; likewise, self-medication without medical prescription increased from 15.8% to 47.7%, the consumption of anxiolytics or antidepressants increased from 0.8% to 26.3% caused by the symptoms of anxiety.</p> <p><strong>Conclusion:</strong> It was determined that there is a moderate relationship between self-medication and anxiety symptoms in the context of COVID-19, in users who go to a drugstore in Los Olivos, Lima 2021.</p> <p><strong>Keywords:</strong> Self-medication, prescription, anxiety, depression, COVID-19.</p> <p><strong>Background:</strong> To determine the relationship between self-medication and anxiety symptoms in the context of COVID-19, in users who go to a drugstore in Los Olivos, Lima 2021.</p> <p><strong>Methods:</strong> The research method was deductive, basic and with a quantitative approach; the design used was non-experimental, descriptive, correlational, cross-sectional, and prospective. Spearman's Rho analysis was performed to validate the hypothesis.</p> <p><strong>Results:</strong> 384 users were evaluated, finding 93.5% aged 18-59 years, of whom 53.4% were female, 42.7% had completed high school, 57.8% were single and 51.6% presented physical symptoms, preferably muscular tension accompanied by pain, 60.7% presented behavioral symptoms, highlighting unusual sadness in the face of COVID-19 and 70.1% presented cognitive symptoms with greater frequency of concern about contracting COVID-19. In addition, the greater the symptoms of anxiety, the higher the self-medication increased from 9.0% to 21.1%, a similar case was evidenced in self-medication on their own initiative where the increase was from 7.5% to 33.3%; likewise, self-medication without medical prescription increased from 15.8% to 47.7%, the consumption of anxiolytics or antidepressants increased from 0.8% to 26.3% caused by the symptoms of anxiety.</p> <p><strong>Conclusion:</strong> It was determined that there is a moderate relationship between self-medication and anxiety symptoms in the context of COVID-19, in users who go to a drugstore in Los Olivos, Lima 2021</p> <p> </p>
Dataset from: "Assessment of depression, anxiety, and psychological symptoms in parents of pediatric palliative care patients: A single-center case-control study"
<p>The dataset comprises raw data from a case-control study that compared levels of depression, anxiety, and general psychological symptoms between parents of pediatric palliative care (PPC) patients and parents of healthy controls.</p> <p>Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), and Symptom Checklist-90 Revised (SCL-90-R) were employed to provide a comprehensive and nuanced understanding of the mental health challenges faced by parents.</p> <p>The designation "case" in the first column (A) represents the parents of PPC patients, while the designation "control" represents the control group. The columns labeled B to S present demographic characteristics data, while columns T to AR present inventory scores. Columns BB to GC, in turn, present the responses to the inventory items.</p> <p> </p> <p> </p>
Design and Development of a Smartphone-Based Geolocalized Exposure Therapy Software for Anxiety Disorders: SyMptOMS-ET -- Reproducibility Package
<p>R Notebook and datasets for the submitted paper "<em>Towards a self-applied, mobile-based geolocated exposure therapy software for anxiety disorders: SyMptOMS-ET app</em>"</p> <blockquote> <p>Alberto González-Pérez, Laura Diaz-Sanahuja, Miguel Matey-Sanz, Jorge Osma, Carlos Granell, Juana Bretón-López, Sven Casteleyn. Towards a self-applied, mobile-based geolocated exposure therapy software for anxiety disorders: SyMptOMS-ET app. <a href="https://journals.sagepub.com/home/dhj">Digital Health Journal</a> [Submitted]</p> </blockquote> <p>Experiments were conducted using the v1.2.0 version of the SyMptOMS-ET open-source app, which can be found <a href="https://github.com/GeoTecINIT/symptoms-mobile-app/releases/tag/v1.2.0">here</a>.</p>
The prevalence and correlates of depression and anxiety symptoms among older adults in Shenzhen, China
Open the record for dataset details and reuse information.
Patient-reported outcomes via electronic health record portal vs. telephone: process and retention data in a pilot trial of anxiety or depression symptoms in epilepsy
<p>Objective: To close gaps between research and clinical practice, tools are needed for efficient pragmatic trial recruitment and patient-reported outcome(PROM) collection. The objective was to assess feasibility and process measures for patient-reported outcome collection in a randomized trial comparing electronic health record(EHR) patient portal questionnaires to telephone interview among adults with epilepsy and anxiety or depression symptoms.</p> <p>Results: Participants were 60% women, 77% White/non-Hispanic, with mean age 42.5 years. Among 15 individuals randomized to EHR portal, 10(67%, CI 41.7-84.8%) met the 6-month retention endpoint, versus 100%(CI 79.6-100%) in the telephone group(p=0.04). EHR outcome collection at 6 months required 11.8 minutes less research staff time per participant than telephone (5.9, CI 3.3-7.7 vs. 17.7, CI 14.1-20.2). Subsequent telephone contact after unsuccessful EHR attempts enabled near complete data collection and still saved staff time.</p> <p>Discussion: Data from this randomized pilot study of pragmatic outcome collection methods for patients with anxiety or depression symptoms in epilepsy includes baseline participant characteristics, recruitment flow resulting from a novel EHR-based, care-embedded recruitment process, and data on retention along with various process measures at 6-months.</p>
Adverse childhood events and clinical manifestation of anxiety symptoms in Greek adolescents during COVID-19 pandemic
<p><strong>Background: </strong>Adverse Childhood Experiences (ACEs) are linked to the development of Anxiety in Adolescence. According to recent studies, the pandemic COVID-19 is a novel ACE that has increased Anxiety among adolescents. This study aims to investigate the relationship between Adverse Childhood Experiences (ACEs) and COVID-19 in the development of Anxiety in Adolescence. <strong>Methods: </strong>A cross-sectional study with a community sample of 248 boys and girls aged 12 to 15 years (Mean: 13.50 years) from five High Schools in Eastern Attica were conducted. A total of four questionnaires were used: 1) Demographic Questionnaire, 2) State-Trait-Anxiety-Inventory for Children – STAIC, 3) Adverse Childhood Experiences Scale, and 4) COVID-19 Impact Scale. <strong>Results: </strong>The results demonstrated a strong correlation between the total number of adverse childhood experiences (ACEs) and Anxiety (Trait and State) in adolescence (Trait Anxiety: rho=.37, p0.001; State Anxiety: rho=.29, p0.001). Girls scored substantially higher on Trait Anxiety (U = 4353, p 0.001) and State Anxiety (U = 5822.5, p = 0.014) than boys. Girls also demonstrated more significant Anxiety than boys. The number of adverse childhood experiences was found to be significantly related to the impact of COVID-19 (=0.025, p 0.001). <strong>Conclusions: </strong>The present study's findings can be used to design and implement future effective, preventive, and therapeutic programs for adolescents with anxiety symptoms who were exposed to a variety of Adverse Childhood Experiences and the COVID-19 pandemic during their adolescence.</p>
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms
ClinicalTrials.gov study NCT02013531. IPD Sharing: Not stated. Countries: 1. Publications: 2.
A Dose-Finding Study of MM-120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms
ClinicalTrials.gov study NCT05407064. IPD Sharing: NO. Countries: 1. Publications: 1.
Does Treating Anxiety Symptoms With ACT Improve Vascular Inflammation and Function?
ClinicalTrials.gov study NCT02915874. IPD Sharing: NO. Countries: 1. Publications: 2.
Transdiagnostic Internet Cognitive-behavior Therapy for Mixed Anxiety and Depressive Symptoms in Postnatal Women
ClinicalTrials.gov study NCT06778096. IPD Sharing: NO. Countries: 1. Publications: 2.
Assessing Neuropsychiatric Symptoms Including Depression, Anxiety, Irritability, and Suicidal Thoughts or Behavior in Subjects Quitting Smoking on Varenicline Tartrate or Placebo
ClinicalTrials.gov study NCT00749944. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Dis
ClinicalTrials.gov study NCT00266409. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Open-Label Study to Evaluate the Effect of Treatment With Fentanyl Buccal Tablets on Pain Anxiety Symptoms When Used for the Management of Breakthrough Pain
ClinicalTrials.gov study NCT00387010. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Patient-reported outcomes via electronic health record portal vs. telephone: process and retention data in a pilot trial of anxiety or depression symptoms in epilepsy
Open the record for dataset details and reuse information.
The Prevalence and Impact of Depression and Anxiety Symptoms in Patients With Non-CF Bronchiectasis
ClinicalTrials.gov study NCT01688180. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Effects of an Integrative Treatment Model to Reduce Anxiety and Depression in Minor Mental Health Problems and Medically Unexplained Symptoms
ClinicalTrials.gov study NCT01631500. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Anxiety Symptoms in Relation to Use of Hemp-derived, Full Spectrum Cannabidiol (CBD)
ClinicalTrials.gov study NCT05023759. IPD Sharing: YES. Countries: 2. Publications: 5.
Symptom-specific TMS Targets for Depression and Anxiety
ClinicalTrials.gov study NCT04604210. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.